Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function-Reference-Cited by-同舟云学术

Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function

Published:2017-07-03 Issue:11 Volume:17 Page:2922-2936
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Adams A. B.¹,Goldstein J.¹,Garrett C.¹,Zhang R.²,Patzer R. E.¹²,Newell K. A.¹,Turgeon N. A.¹,Chami A. S.¹³,Guasch A.¹³,Kirk A. D.⁴,Pastan S. O.¹³,Pearson T. C.¹,Larsen C. P.¹

Affiliation:

1. Emory Transplant Center; Emory University; Atlanta GA

2. School of Public Health; Emory University; Atlanta GA

3. Renal Division; Department of Medicine; Emory University; Atlanta GA

4. Department of Surgery; Duke University; Durham NC

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajt.14353/fullpdf

Reference26 articles.

1. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant;Wolfe;N Engl J Med,1999

2. Systematic review: Kidney transplantation compared with dialysis in clinically relevant outcomes;Tonelli;Am J Transplant,2011

3. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era;Meier-Kriesche;Am J Transplant,2004

4. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies?;Meier-Kriesche;Am J Transplant,2004

5. Kidney;Hart;Am J Transplant,2016

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist;Advances in Kidney Disease and Health;2024-09

2. Belatacept based immunosuppression: What and when to combine?;Transplant Immunology;2024-08

3. Belatacept‐based immunosuppression does not confer increased risk of BK polyomavirus‐DNAemia relative to tacrolimus‐based immunosuppression;Transplant Infectious Disease;2024-06-30

4. Zusammenfassung der 2. internationalen Konsensusleitlinie zum Management von BK-Polyomavirus bei Patienten nach Nierentransplantation;Die Nephrologie;2024-06-26

5. Obesity is associated with a higher incidence of rejection in patients on belatacept: A pooled analysis from the BENEFIT/BENEFIT-EXT clinical trials;American Journal of Transplantation;2024-06